↓ Skip to main content

Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, December 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 489)
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

policy
1 policy source
twitter
15 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Marketing authorization of COVID-19 vaccines across UK, EU, and the US: fact-checking and the implications for future research
Published in
Journal of Pharmaceutical Policy and Practice, December 2021
DOI 10.1186/s40545-021-00400-0
Pubmed ID
Authors

Nasir Abbas, Zaheer-Ud-Din Babar

X Demographics

X Demographics

The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 2 13%
Researcher 2 13%
Student > Bachelor 1 7%
Unknown 10 67%
Readers by discipline Count As %
Medicine and Dentistry 2 13%
Social Sciences 1 7%
Biochemistry, Genetics and Molecular Biology 1 7%
Unknown 11 73%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2023.
All research outputs
#2,233,331
of 25,163,621 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#48
of 489 outputs
Outputs of similar age
#53,089
of 513,997 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#2
of 22 outputs
Altmetric has tracked 25,163,621 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 489 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 513,997 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.